Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Sinobiopharma Signs Deal for New Hypertension Drug

publication date: Aug 12, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sinobiopharma, Inc., a US-headquartered company that operates entirely in China, will co-develop, manufacture and commercialize Eplerenone, with Jiangsu Lianhuan Pharmaceuticals Co. Eplerenone is an aldosterone antagonist used as an adjunct to treat hypertension and heart failure. Sinobiopharma will receive 60% of the profits. More details....

Stock Symbol: (OTCBB: SNBP)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners